HC Wainwright Reaffirms “Buy” Rating for aTyr Pharma (NASDAQ:LIFE)

HC Wainwright restated their buy rating on shares of aTyr Pharma (NASDAQ:LIFE) in a research note released on Friday morning, Benzinga reports. HC Wainwright currently has a $35.00 price target on the biotechnology company’s stock.

Separately, Royal Bank of Canada reduced their price target on shares of aTyr Pharma from $19.00 to $16.00 and set an outperform rating for the company in a research note on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, aTyr Pharma presently has a consensus rating of Hold and a consensus target price of $23.67.

aTyr Pharma Trading Up 3.1 %

LIFE opened at $1.66 on Friday. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $1.76 and its 200 day moving average price is $1.55. aTyr Pharma has a fifty-two week low of $1.08 and a fifty-two week high of $2.70.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.11 million. Equities research analysts predict that aTyr Pharma will post -0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LIFE. SG Americas Securities LLC bought a new stake in shares of aTyr Pharma during the 1st quarter worth $55,000. GSA Capital Partners LLP lifted its holdings in shares of aTyr Pharma by 105.3% during the first quarter. GSA Capital Partners LLP now owns 224,147 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 114,983 shares during the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of aTyr Pharma in the 1st quarter valued at $117,000. Pale Fire Capital SE raised its holdings in aTyr Pharma by 425.8% during the 4th quarter. Pale Fire Capital SE now owns 293,706 shares of the biotechnology company’s stock worth $414,000 after buying an additional 237,849 shares during the period. Finally, Granite Bay Wealth Management LLC purchased a new stake in aTyr Pharma during the fourth quarter valued at about $25,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.